Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03015844
Expanded Access Status : Available
First Posted : January 10, 2017
Last Update Posted : March 13, 2019
Sponsor:
Collaborator:
Cohen Children's Medical Center
Information provided by (Responsible Party):
Julie Krystal, Northwell Health

Brief Summary:
This is an expanded access protocol/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Response rate, toxicity, and time to progression and death will be evaluated.

Condition or disease Intervention/treatment
Neuroblastoma Pheochromocytoma Drug: 131-I-meta-iodobenzylguanidine

Layout table for study information
Study Type : Expanded Access
Official Title: A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma



Intervention Details:
  • Drug: 131-I-meta-iodobenzylguanidine
    Other Names:
    • 131I-MIBG
    • Iobenguane

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   365 Days to 29 Years   (Child, Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Diagnosis: Relapsed/Refractory neuroblastoma, with an original diagnosis made histologically or from elevated urine catecholamines with abnormal tumor cells in bone marrow OR relapsed/refractory pheochromocytoma.
  • Disease status: Progressive disease at any time (defined as any new lesion or an increase in size by >25% of pre-existing disease), or a failure to respond to standard therapy. Patients must have evidence of MIBG uptake into tumor at ≥ one site within 6 weeks prior to entry on study and subsequent to any intervening therapy
  • Prior therapy: A minimum of two weeks since should have elapsed since any chemotherapy causing myelosuppression. It must be a minimum of three months since receiving radiation to any of the following fields: craniospinal, total abdominal, whole lung, total body irradiation. For any other sites of radiation, at least 2 weeks should have elapsed. For patients who received radiation to the only site of MIBG-avid disease within two months of study entry, biopsy confirmation of residual active disease is required, with positive bone marrow being sufficient. At least 7 days should have elapsed since completion of therapy with a biologic agent and at least 3 half-lives should have elapsed since therapy with a monoclonal antibody. No cytokine therapy may be given within 24 hours of receiving 131I-MIBG. Patients may have received prior MIBG therapy, provided they demonstrated a response or stable disease initially, with progressive disease occurring at least 35 days following treatment.
  • Organ function: ANC >500/uL, platelets >20,000/uL with transfusion allowed. Bilirubin ≤2x ULN, AST/ALT ≤10x ULN.Serum Creatinine ≤2x ULN OR 24-hour creatinine clearance OR GFR ≥60ml/min/1.73m2. Normal lung function demonstrated by no dyspnea, exercise intolerance or oxygen requirement. Oxygen saturation ≥94% on room air. No clinically significant cardiac dysfunction and ejection fraction ≥45% on echocardiogram.
  • Stem cells: Patients must have a minimum of 2.0 x106/kg viable CD34+ peripheral blood stem cells for re-infusion following 131I-MIBG. An additional back-up of 2.0x106/kg CD34+ cells is recommended but not required.
  • Life expectancy longer than 8 weeks,Karnofsky or Lansky performance status of ≥ 50%

Exclusion Criteria:

  • Pregnant or lactating patients
  • Disease of any organ system that would compromise the patient's ability to participate in the study, including hemodialysis. Significant organ impairment should be discussed with the Principal Investigator prior to study entry
  • Patients with active grade 3-4 infection, as defined by the NCI CTCAE V4.0.
  • Patients with known MBIG-avid brain parenchymal disease (leptomeningeal or skull based metastases are eligible).
  • In patients with metastatic pheochromocytoma, a urinalysis must be preformed prior to study enrollment. If proteinuria is present, a 24 hour urine must be collected and total protein determined. If the 24-hour urine protein is above the institutional upper limit of normal, the patient is excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03015844


Contacts
Layout table for location contacts
Contact: Julie Krystal, MD, MPH 718-470-3460 jkrystal12@northwell.edu
Contact: Jonathan Fish, MD 718-470-3460 Jfish1@northwell.edu

Locations
Layout table for location information
United States, New York
Cohen Children's Medical Center
New Hyde Park, New York, United States, 11040
Sponsors and Collaborators
Northwell Health
Cohen Children's Medical Center

Publications:

Layout table for additonal information
Responsible Party: Julie Krystal, Director of Developmental Therapeutics, Pediatric Hematology-Oncology, Northwell Health
ClinicalTrials.gov Identifier: NCT03015844     History of Changes
Other Study ID Numbers: CCMC1611
First Posted: January 10, 2017    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019

Keywords provided by Julie Krystal, Northwell Health:
MIBG
131I-MIBG
relapsed
neuroblastoma
pheochromocytoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroblastoma
3-Iodobenzylguanidine
Pheochromocytoma
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Paraganglioma
Neuroendocrine Tumors
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Radiopharmaceuticals